A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

Clinical trial NCT04740671 · COMPLETED

Trial details

NCT number: NCT04740671
Sponsor: Shanghai Henlius Biotech
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Age Related Macular Degeneration

Start date: 2021-07-01
Primary completion: 2024-12-31
Enrollment: 410

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.